A high dose of sickle cell drug pociredir boosted fetal hemoglobin and reduced red blood cell destruction in adults with ...

A clinical trial testing the oral therapy tebapivat for sickle cell disease is fully enrolled, with early results expected later this year.

As they shift from pediatric to adult care, young adult patients with sickle cell disease appear to visit the ER more often, a study found.

The first participant with sickle cell disease (SCD) has been dosed in a clinical trial of HBI-002, an experimental, low-dose, oral liquid formulation of carbon monoxide being developed by Hillhurst ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Top-line data revealed olinciguat was well-tolerated across all doses tested, but the therapy’s ...

FTX-6058 is an experimental small molecule treatment for sickle cell disease (SCD) being developed by Fulcrum Therapeutics. It aims to treat patients by raising levels of fetal hemoglobin in cells.

A sickle cell disease (SCD) patient in Bahrain received the gene-editing therapy Casgevy (exagamglogene autotemcel), becoming the first patient outside the U.S. to be treated with the drug. Bahrain ...

Researchers from the University of Illinois Chicago (UIC) have received $3.78 million in federal funding to evaluate whether a diabetes medication can slow kidney damage in people with sickle cell ...

Children’s Hospital Los Angeles (CHLA) is now offering Casgevy (exagamglogene autotemcel), an approved gene-editing therapy for sickle cell disease (SCD). “This is a transformative time for Children’s ...

Sickle cell disease (SCD) may be cured in some individuals by a stem cell transplant. There also are several approved therapies to help manage the condition and its related complications. Some of the ...

Bluebird Bio and Xcellbio have entered into an agreement to support the commercialization of Lyfgenia (lovotibeglogene autotemcel), Bluebird’s gene therapy for sickle cell disease, incorporating ...

As a medical professional living with sickle cell anemia, I’ve chosen to dedicate myself to sickle cell advocacy and education. On this journey, I’ve realized a lot of people cannot distinguish ...